Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays

Journal of Clinical Microbiology

Volumn 50, Issue 6, 2012, Pages 1943-1949

  Murayama, Asako ^a   Sugiyama, Nao ^a   Watashi, Koichi ^a   Masaki, Takahiro ^a   Suzuki, Ryosuke ^a   Aizaki, Hideki ^a   Mizuochi, Toshiaki ^a   Wakita, Takaji ^a   Kato, Takanobu ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC POLYMORPHISM; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; JAPANESE; LIMIT OF DETECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REFERENCE VALUE; RNA ANALYSIS; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; VIRUS LOAD;

BLOOD; CLINICAL LABORATORY TECHNIQUES; HEPACIVIRUS; HEPATITIS C; HUMANS; JAPAN; REFERENCE STANDARDS; RNA, VIRAL; VIRAL CORE PROTEINS; VIROLOGY;

HEPATITIS C VIRUS;

EID: 84862088080     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00487-12     Document Type: Article

References (35)

1. Alvarez M, Planelles D, Vila E, Montoro J, Franco E. 2004. Prolonged hepatitis C virus seroconversion in a blood donor, detected by HCV antigen test in parallel with HCV RNA. Vox Sang. 86:266-267. (Pubitemid 38902099)
2. Aoyagi K, et al. 1999. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J. Clin. Microbiol. 37:1802-1808. (Pubitemid 29235226)
3. Aoyagi K, et al. 2001. Performance of a conventional enzyme immuno-assay for hepatitis C virus core antigen in the early phases of hepatitis C infection. Clin. Lab. 47:119-127. (Pubitemid 32236958)
4. Bossler A, et al. 2011. Performance of the COBAS(R) AmpliPrep/COBAS TaqMan(R) automated system for hepatitis C virus (HCV) quantification in a multi-center comparison. J. Clin. Virol. 50:100-103.
5. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. 2007. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 46: 22-31. (Pubitemid 47171917)
6. Elkady A, et al. 2010. Performance of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA: evaluation on HCV genotypes 1-4. J. Med. Virol. 82:1878-1888.
7. Enomoto M, et al. 2005. Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads. J. Med. Virol. 77:77-82. (Pubitemid 41076480)
8. Feld JJ, Hoofnagle JH. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972. (Pubitemid 41191673)
9. Feld JJ, Liang TJ. 2006. Hepatitis C-identifying patients with progressive liver injury. Hepatology 43:S194 -S206.
10. Icardi G, et al. 2001. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J. Clin. Microbiol. 39:3110-3114. (Pubitemid 32830301)
11. Ikeda K, et al. 1996. Hepatitis C virus subtype 3b infection in a hospital in Japan: epidemiological study. J. Gastroenterol. 31:801-805. (Pubitemid 27042258)
12. Kaiser T, et al. 2008. Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis. J. Med. Virol. 80:1195-1201. (Pubitemid 351705998)
13. Leary TP, et al. 2006. A chemiluminescent, magnetic particle-based immunoassay for the detection of hepatitis C virus core antigen in human serum or plasma. J. Med. Virol. 78:1436-1440. (Pubitemid 44533872)
14. Liang TJ. 1998. Combination therapy for hepatitis C infection. N. Engl. J. Med. 339:1549-1550. (Pubitemid 28543507)
15. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132:296-305. (Pubitemid 30106261)
16. Matsuura K, et al. 2009. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J. Clin. Microbiol. 47:385-389.
17. Mederacke I, et al. 2009. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J. Clin. Virol. 46:210-215.
18. Medici MC, et al. 2011. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J. Clin. Virol. 51:264-269.
19. Miedouge M, et al. 2010. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J. Clin. Virol. 48: 18-21.
20. Morota K, et al. 2009. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J. Virol. Methods 157:8-14.
21. Moscato GA, et al. 2011. Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C. Intervirology 54: 61-65.
22. Nubling CM, Unger G, Chudy M, Raia S, Lower J. 2002. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 42:1037-1045.
23. Ogata N, Alter HJ, Miller RH, Purcell RH. 1991. Nucleotide sequence and mutation rate of theHstrain of hepatitisCvirus. Proc. Natl. Acad. Sci. U. S. A. 88:3392-3396. (Pubitemid 21916627)
24. Park Y, Lee JH, Kim BS, Kim DY, Han KH, Kim HS. 2010. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J. Clin. Microbiol. 48:2253-2256.
25. Pawlotsky JM. 2006. Therapy of hepatitis C: from empiricism to eradication. Hepatology 43:S207-S220.
26. Robertson B, et al. 1998. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch. Virol. 143:2493-2503. (Pubitemid 29022697)
27. Ross RS, et al. 2010. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J. Clin. Microbiol. 48:1161-1168.
28. Saeed M, et al. 2009. Evaluation of hepatitis C virus core antigen assays in detecting recombinant viral antigens of various genotypes. J. Clin. Microbiol. 47:4141- 4143.
29. Seeff LB, Hoofnagle JH. 2002. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 36:S1-S2. (Pubitemid 35253458)
30. Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H. 2005. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J. Clin. Microbiol. 43:186-191.
31. Tanaka E, et al. 2000. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 32:388 -393.
32. Tanaka Y, et al. 2003. High stability of enzyme immunoassay for hepatitis C virus core antigen-evaluation before and after incubation at room temperature. Hepatol. Res. 26:261-267. (Pubitemid 37184513)
33. Vermehren J, et al. 2008. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/ Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J. Clin. Microbiol. 46:3880-3891.
34. Vermehren J, et al. 2011. Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J. Clin. Microbiol. 49:3309-3315.
35. Vermehren J, et al. 2011. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J. Clin. Virol. 52:133-137.